{
    "references": [
        {
            "bibentry": "Griffith, B, Pendyala, S, Hecker, L, et al. NOX enzymes and pulmonary disease. Antioxid Redox Signal 2009; 11: 2505–16. PMID: 19331546",
            "process_entry": "True",
            "doi": "10.1089/ars.2009.2599",
            "pmid": "19331546",
            "pmcid": "PMC2821137",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Xu, L, Li, Y, Wan, S, et al. Protective effects of apocynin nitrone on acute lung injury induced by lipopolysaccharide in rats. Int Immunopharmacol 2014; 20: 377–82. PMID: 24704624",
            "process_entry": "True",
            "doi": "10.1016/j.intimp.2014.03.014",
            "pmid": "24704624",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Bux, J, Sachs, UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007; 136: 788–99. PMID: 17341264",
            "process_entry": "True",
            "doi": "10.1111/j.1365-2141.2007.06492.x",
            "pmid": "17341264",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Force, ADT, Ranieri, VM, Rubenfeld, GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012; 307: 2526–33. PMID: 22797452",
            "process_entry": "True",
            "doi": "10.1001/jama.2012.5669",
            "pmid": "22797452",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Eckle, T, Koeppen, M, Eltzschig, HK. Role of extracellular adenosine in acute lung injury. Physiology (Bethesda) 2009; 24: 298–306. PMID: 19815856",
            "process_entry": "True",
            "doi": "10.1152/physiol.00022.2009",
            "pmid": "19815856",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Neudecker, V, Brodsky, KS, Clambey, ET, et al. Neutrophil transfer of miR-223 to lung epithelial cells dampens acute lung injury in mice. Sci Transl Med 2017; 9: 408.",
            "process_entry": "True",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Wheeler, AP, Bernard, GR, Thompson, BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354: 2213–24. PMID: 16714768",
            "process_entry": "True",
            "doi": "10.1056/nejmoa061895",
            "pmid": "16714768",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Richeldi, L, Du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–82. PMID: 24836310",
            "process_entry": "True",
            "doi": "10.1056/nejmoa1402584",
            "pmid": "24836310",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Shi, JB, Chen, LZ, Wang, BS, et al. Novel pyrazolo[4,3-d]pyrimidine as potent and orally active inducible nitric oxide synthase (iNOS) dimerization inhibitor with efficacy in rheumatoid arthritis mouse model. J Med Chem 2019; 62: 4013–31. PMID: 30925056",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.9b00039",
            "pmid": "30925056",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Xing, Z, Han, J, Hao, X, et al. Immature monocytes contribute to cardiopulmonary bypass-induced acute lung injury by generating inflammatory descendants. Thorax 2017; 72: 245–55. PMID: 27660037",
            "process_entry": "True",
            "doi": "10.1136/thoraxjnl-2015-208023",
            "pmid": "27660037",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Imai, Y, Kuba, K, Neely, GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133: 235–49. PMID: 18423196",
            "process_entry": "True",
            "doi": "10.1016/j.cell.2008.02.043",
            "pmid": "18423196",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Lamkanfi, M. Emerging inflammasome effector mechanisms. Nat Rev Immunol 2011; 11: 213–20. PMID: 21350580",
            "process_entry": "True",
            "doi": "10.1038/nri2936",
            "pmid": "21350580",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Liu, Z, Tang, L, Zhu, H, et al. Design, synthesis, and structure-activity relationship study of novel indole-2-carboxamide derivatives as anti-inflammatory agents for the treatment of sepsis. J Med Chem 2016; 59: 4637–50. PMID: 27142640",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.5b02006",
            "pmid": "27142640",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Schenone, S, Radi, M, Musumeci, F, et al. Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies. Chem Rev 2014; 114: 7189–238. PMID: 24873489",
            "process_entry": "True",
            "doi": "10.1021/cr400270z",
            "pmid": "24873489",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Advani, RH, Buggy, JJ, Sharman, JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88–94. PMID: 23045577",
            "process_entry": "True",
            "doi": "10.1200/JCO.2012.42.7906",
            "pmid": "23045577",
            "pmcid": "PMC5505166",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Park, H-K, Jeong, H, Ko, E, et al. Paralog specificity determines subcellular distribution, action mechanism, and anticancer activity of TRAP1 inhibitors. J Med Chem 2017; 60: 7569–78. PMID: 28816449",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.7b00978",
            "pmid": "28816449",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Wyllie, S, Thomas, M, Patterson, S, et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature 2018; 560: 192–7. PMID: 30046105",
            "process_entry": "True",
            "doi": "10.1038/s41586-018-0356-z",
            "pmid": "30046105",
            "pmcid": "PMC6402543",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Markwalder, JA, Arnone, MR, Benfield, PA, et al. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. J Med Chem 2004; 47: 5894–911. PMID: 15537345",
            "process_entry": "True",
            "doi": "10.1021/jm020455u",
            "pmid": "15537345",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Abdelazeem, AH, Abdelatef, SA, El-Saadi, MT, et al. Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents. Eur J Pharm Sci 2014; 62: 197–211. PMID: 24907682",
            "process_entry": "True",
            "doi": "10.1016/j.ejps.2014.05.025",
            "pmid": "24907682",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Hulverson, MA, Bruzual, I, McConnell, EV, et al. Pharmacokinetics and in vivo efficacy of pyrazolopyrimidine, pyrrolopyrimidine and 5-aminopyrazole-4-carboxamide bumped kinase inhibitors against toxoplasmosis. J Infect Dis 2019; 219: 1464–1473. PMID: 30423128",
            "process_entry": "True",
            "doi": "10.1093/infdis/jiy664",
            "pmid": "30423128",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Shi, JB, Tang, WJ, Qi, XB, et al. Novel pyrazole-5-carboxamide and pyrazole-pyrimidine derivatives: synthesis and anticancer activity. Eur J Med Chem 2015; 90: 889–96. PMID: 25554922",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.12.013",
            "pmid": "25554922",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Tham, CL, Lam, KW, Rajajendram, R, et al. The effects of a synthetic curcuminoid analogue, 2,6-bis-(4-hydroxyl-3-methoxybenzylidine)cyclohexanone on proinflammatory signaling pathways and CLP-induced lethal sepsis in mice. Eur J Pharmacol 2011; 652: 136–44. PMID: 21114991",
            "process_entry": "True",
            "doi": "10.1016/j.ejphar.2010.10.092",
            "pmid": "21114991",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Bukhari, SN, Lauro, G, Jantan, I, et al. Pharmacological evaluation and docking studies of alpha,beta-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A(2), cyclooxygenases, lipoxygenase and proinflammatory cytokines. Bioorg Med Chem 2014; 22: 4151–61. PMID: 24938495",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2014.05.052",
            "pmid": "24938495",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Mohd Aluwi, MFF, Rullah, K, Yamin, BM, et al. Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines. Bioorg Med Chem Lett 2016; 26: 2531–8. PMID: 27040659",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2016.03.092",
            "pmid": "27040659",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Wang, JL, Carter, J, Kiefer, JR, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate. Bioorg Med Chem Lett 2010; 20: 7155–8. PMID: 21055613",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2010.07.053",
            "pmid": "21055613",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Nagy, G, Clark, JM, Buzas, EI, et al. Nitric oxide, chronic inflammation and autoimmunity. Immunol Lett 2007; 111: 1–5. PMID: 17568690",
            "process_entry": "True",
            "doi": "10.1016/j.imlet.2007.04.013",
            "pmid": "17568690",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Pan, J, Xu, T, Xu, F, et al. Development of resveratrol-curcumin hybrids as potential therapeutic agents for inflammatory lung diseases. Eur J Med Chem 2017; 125: 478–91. PMID: 27689730",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2016.09.033",
            "pmid": "27689730",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Yang, HZ, Wang, JP, Mi, S, et al. TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury. Am J Pathol 2012; 180: 275–92. PMID: 22062220",
            "process_entry": "True",
            "doi": "10.1016/j.ajpath.2011.09.019",
            "pmid": "22062220",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Chen, LZ, Sun, WW, Bo, L, et al. New arylpyrazoline-coumarins: synthesis and anti-inflammatory activity. Eur J Med Chem 2017; 138: 170–81. PMID: 28667873",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.06.044",
            "pmid": "28667873",
            "xmlid": "CIT0029"
        }
    ],
    "localid": "MED-31117832",
    "doi": "10.1080/14756366.2019.1618291",
    "pmid": "10.1080/14756366.2019.1618291",
    "pmcid": "31117832",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31117832/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,204)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,204)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0002",
                "rp_string": "2–4",
                "pl_string": "Acute lung injury (ALI), characterized by increased permeability of endothelium and epithelium as well as loss of vascular integrity, is an acute inflammatory disease with high morbidity and mortality1,2. ALI is directly or indirectly caused by pneumonia, inhalation injury, drowning and so forth2–4, which clinical manifestations include pulmonary edema, dyspnea, hypoxemia5–7. Many therapies for ALI have been conducted, but effective therapeutic agents were not discovered up to now8. Recently, several studies have shown that various inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), play a pivotal role in the development and progrossion of ALI9–11. Increasing evidences showed that suppressing the over-secretion of inflammatory cytokines have been emeraged as a promising strategy for the treatment of ALI12,13.",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 3,
                "xref_id": "",
                "pl_string": "2–4",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 4,
                "xref_id": "",
                "pl_string": "2–4",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0002",
                "rp_string": "2–4",
                "pl_string": "Acute lung injury (ALI), characterized by increased permeability of endothelium and epithelium as well as loss of vascular integrity, is an acute inflammatory disease with high morbidity and mortality1,2. ALI is directly or indirectly caused by pneumonia, inhalation injury, drowning and so forth2–4, which clinical manifestations include pulmonary edema, dyspnea, hypoxemia5–7. Many therapies for ALI have been conducted, but effective therapeutic agents were not discovered up to now8. Recently, several studies have shown that various inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), play a pivotal role in the development and progrossion of ALI9–11. Increasing evidences showed that suppressing the over-secretion of inflammatory cytokines have been emeraged as a promising strategy for the treatment of ALI12,13.",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "pl_xpath": "/article/body/sec[1]/p[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 7,
                "xref_id": "CIT0005",
                "rp_string": "5–7",
                "pl_string": "Acute lung injury (ALI), characterized by increased permeability of endothelium and epithelium as well as loss of vascular integrity, is an acute inflammatory disease with high morbidity and mortality1,2. ALI is directly or indirectly caused by pneumonia, inhalation injury, drowning and so forth2–4, which clinical manifestations include pulmonary edema, dyspnea, hypoxemia5–7. Many therapies for ALI have been conducted, but effective therapeutic agents were not discovered up to now8. Recently, several studies have shown that various inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), play a pivotal role in the development and progrossion of ALI9–11. Increasing evidences showed that suppressing the over-secretion of inflammatory cytokines have been emeraged as a promising strategy for the treatment of ALI12,13.",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 7,
                "xref_id": "CIT0005",
                "rp_string": "5–7",
                "pl_string": "Acute lung injury (ALI), characterized by increased permeability of endothelium and epithelium as well as loss of vascular integrity, is an acute inflammatory disease with high morbidity and mortality1,2. ALI is directly or indirectly caused by pneumonia, inhalation injury, drowning and so forth2–4, which clinical manifestations include pulmonary edema, dyspnea, hypoxemia5–7. Many therapies for ALI have been conducted, but effective therapeutic agents were not discovered up to now8. Recently, several studies have shown that various inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), play a pivotal role in the development and progrossion of ALI9–11. Increasing evidences showed that suppressing the over-secretion of inflammatory cytokines have been emeraged as a promising strategy for the treatment of ALI12,13.",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "pl_xpath": "/article/body/sec[1]/p[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 8,
                "xref_id": "",
                "pl_string": "5–7",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 9,
                "xref_id": "",
                "pl_string": "5–7",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),206,173)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),380,108)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0009",
                "rp_string": "9–11",
                "pl_string": "9–11",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),489,206)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 12,
                "xref_id": "",
                "pl_string": "9–11",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),489,206)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 13,
                "xref_id": "",
                "pl_string": "9–11",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),489,206)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0009",
                "rp_string": "9–11",
                "pl_string": "9–11",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "pl_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),489,206)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),696,163)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),696,163)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,386)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazolopyrimidine moiety is an important drug-like scaffold14, which have shown a wide range of clinical applications including bruton's tyrosine kinase inhibitor ibrutinib (I)15, tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor (II)16, cyclin-dependent kinase (CDK) inhibitors (III, IV)17,18, anti-inflammation (V)19 and bumped kinase inhibitors (VI, Figure 1)20.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 18,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,386)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazolopyrimidine moiety is an important drug-like scaffold14, which have shown a wide range of clinical applications including bruton's tyrosine kinase inhibitor ibrutinib (I)15, tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor (II)16, cyclin-dependent kinase (CDK) inhibitors (III, IV)17,18, anti-inflammation (V)19 and bumped kinase inhibitors (VI, Figure 1)20.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 19,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,386)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazolopyrimidine moiety is an important drug-like scaffold14, which have shown a wide range of clinical applications including bruton's tyrosine kinase inhibitor ibrutinib (I)15, tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor (II)16, cyclin-dependent kinase (CDK) inhibitors (III, IV)17,18, anti-inflammation (V)19 and bumped kinase inhibitors (VI, Figure 1)20.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 20,
                "xref_id": "CIT0017",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,386)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazolopyrimidine moiety is an important drug-like scaffold14, which have shown a wide range of clinical applications including bruton's tyrosine kinase inhibitor ibrutinib (I)15, tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor (II)16, cyclin-dependent kinase (CDK) inhibitors (III, IV)17,18, anti-inflammation (V)19 and bumped kinase inhibitors (VI, Figure 1)20.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 21,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,386)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazolopyrimidine moiety is an important drug-like scaffold14, which have shown a wide range of clinical applications including bruton's tyrosine kinase inhibitor ibrutinib (I)15, tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor (II)16, cyclin-dependent kinase (CDK) inhibitors (III, IV)17,18, anti-inflammation (V)19 and bumped kinase inhibitors (VI, Figure 1)20.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 22,
                "xref_id": "CIT0019",
                "rp_string": "19",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,386)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazolopyrimidine moiety is an important drug-like scaffold14, which have shown a wide range of clinical applications including bruton's tyrosine kinase inhibitor ibrutinib (I)15, tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor (II)16, cyclin-dependent kinase (CDK) inhibitors (III, IV)17,18, anti-inflammation (V)19 and bumped kinase inhibitors (VI, Figure 1)20.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 23,
                "xref_id": "CIT0020",
                "rp_string": "20",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,386)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazolopyrimidine moiety is an important drug-like scaffold14, which have shown a wide range of clinical applications including bruton's tyrosine kinase inhibitor ibrutinib (I)15, tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor (II)16, cyclin-dependent kinase (CDK) inhibitors (III, IV)17,18, anti-inflammation (V)19 and bumped kinase inhibitors (VI, Figure 1)20.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 24,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,110)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 25,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[4]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[1]/p),1,115)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 26,
                "xref_id": "CIT0022",
                "rp_string": "22",
                "rp_xpath": "/article/body/sec[4]/sec[2]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[2]/p),1,165)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibitory activity against LPS-induced NO release"
                ]
            }
        ],
        [
            {
                "n_rp": 27,
                "xref_id": "CIT0023",
                "rp_string": "23",
                "rp_xpath": "/article/body/sec[4]/sec[2]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[2]/p),1,165)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibitory activity against LPS-induced NO release"
                ]
            }
        ],
        [
            {
                "n_rp": 28,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[4]/sec[2]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[2]/p),167,101)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibitory activity against LPS-induced NO release"
                ]
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0025",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[4]/sec[4]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[4]/p),1,179)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibition of LPS-induced release of cytokines"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0026",
                "rp_string": "26–28",
                "pl_string": "26–28",
                "rp_xpath": "/article/body/sec[4]/sec[5]/p/xref[1]",
                "pl_xpath": "/article/body/sec[4]/sec[5]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[5]/p),1,257)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibition of LPS-induced TLR4 expression"
                ]
            },
            {
                "n_rp": 31,
                "xref_id": "",
                "pl_string": "26–28",
                "pl_xpath": "/article/body/sec[4]/sec[5]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[5]/p),1,257)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibition of LPS-induced TLR4 expression"
                ]
            },
            {
                "n_rp": 32,
                "xref_id": "",
                "pl_string": "26–28",
                "pl_xpath": "/article/body/sec[4]/sec[5]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[5]/p),1,257)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibition of LPS-induced TLR4 expression"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0026",
                "rp_string": "26–28",
                "pl_string": "26–28",
                "rp_xpath": "/article/body/sec[4]/sec[5]/p/xref[1]",
                "pl_xpath": "/article/body/sec[4]/sec[5]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[5]/p),1,257)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibition of LPS-induced TLR4 expression"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[4]/sec[6]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/sec[6]/p),1,94)",
                "containers_title": [
                    "Results and discussion",
                    "Inhibition of LPS-induced p38 signaling pathway"
                ]
            }
        ]
    ]
}